IMMUNOTHERAPY

David L. Bartlett, MD, discussed the adoption of key immunotherapies and how exploration of the tumor microenvironment and immune environment is opening new approaches to treatment in an interview with Targeted Oncology.

The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy.

Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.

Most studies of how timing affects immunotherapy efficacy have defined “timing” relative to other treatments, but some research has investigated the impact of giving patients immunotherapy at different times of day.

The first patient has been enrolled into the PREMIER registry for patients with all stages of cancer.

In an interview with Targeted Oncology, Robert Sackstein, MD, discussed ongoing research around the strategy of targeting the sugar coat of cancer cells to potentially aid in cancer treatment, particularly in hematologic malignancies.

Florida Cancer Specialists & Research Institute sites and site worldwide are now recruiting patients for the PROPHETIC study.

The introduction of CAR engineering to adoptive cell therapy has led to immune effector cell treatments with improved cytotoxicity.

Targeting multiple immune cell pathways may elicit better major pathologic and pathologic complete responses in patient with resectable, early-stage non–small cell lung cancer versus immune checkpoint inhibition alone.

Over the past decade, cancer regimens featuring CTLA-4 inhibitor monotherapy have largely been replaced by combination regimens pairing these agents with anti–PD-1/ PD-L1 antibodies.

Numerous classes of STING agonists are being evaluated for use, including novel cyclic dinucleotides, next-generation noncyclic dinucleotides, bacterial vectors, and ENPP1 inhibitors.

In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.

Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.

In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.

Advances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.

In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.

Bradley J. Monk, MD, FACOG, FACS, discusses the use of immune checkpoint inhibitors to treat cervical cancer.

As part of the larger Resound trial, regorafenib met its primary endpoint in thymic cancer but no patient subset received greater benefits from the drug.

According to Ajjai S. Alva, MBBS, CDK12 is a cell cycle gene that has an important role in RNA polymerase 2 and immunotherapy activity.

Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.

BNT111, an immunotherapy agent under investigation in a phase 2 study, has been granted fast track designation by the FDA.

Novel immuno-oncology agent, COM701 in combination with nivolumab and BMS-986207 may be safe for the treatment of patients with advanced solid tumors.

Phase 2 results presented during the SITC Annual Meeting show that adding intratumoral BO-112 to pembrolizumab in patients with advanced melanoma can induce durable responses.

The biopsy of a 88-year-man demonstrated infiltrative basal cell carcinoma. his case was the topic of discussion during a Case-Based Roundtable led by Nikhil I. Khushalani, MD.

The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.